Sana Biotechnology (SANA) Stock Price, News & Analysis

Company Overview

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cell and gene therapies intended to treat diseases with significant unmet medical needs. The company’s approach is designed to enable the delivery of functional cells or genetic material to patients while addressing challenges such as immune rejection, manufacturing complexity and the need for repeated treatment.

Sana’s research programs include both ex vivo therapies, in which cells are modified outside the body before being administered to a patient, and in vivo therapies, which are designed to modify or deliver therapeutic material directly within the body. Its pipeline has included engineered immune-cell therapies, including investigational CAR T-cell programs, as well as cell-replacement approaches for conditions such as diabetes and other serious diseases.

Founded in 2018 and headquartered in Seattle, Washington, Sana has focused primarily on research and development rather than commercialized products. The company became publicly traded on the Nasdaq under the symbol SANA in 2021. Sana’s operations and clinical development activities are centered in the United States, with its programs subject to regulatory and clinical evaluation. Steve Harr, a co-founder of the company, has served as its chief executive officer.

Key Stats

• Today's Range: $2.86 to $3.00
• 50-Day Range: $2.89 to $4.16
• 52-Week Range: $2.61 to $6.55
• Volume: 3.50 million shs
• Average Volume: 4.08 million shs
• Market Capitalization: $865.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.33
• Consensus Rating: Moderate Buy

Sana Biotechnology Stock Analysis - MarketRank™

Sana Biotechnology scored higher than 42% of companies evaluated by MarketBeat, and ranked 613th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Sana Biotechnology has a consensus price target of $9.33, representing about 223.0% upside from its current price of $2.89.

Amount of Analyst Coverage

Sana Biotechnology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sana Biotechnology are expected to grow in the coming year, from ($0.72) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sana Biotechnology is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sana Biotechnology is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sana Biotechnology has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.53% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 12.22, which indicates bearish sentiment.

Change versus previous month

Short interest in Sana Biotechnology has recently decreased by 0.45%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sana Biotechnology does not currently pay a dividend.

Dividend Growth

Sana Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

17 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sana Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.40% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SANA
• CIK: 1770121
• Web: sana.com
• Phone: 206-701-7914
• Fax: N/A
• Employees: 142
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Sana Biotechnology: $9.33
• High Price Target: $16.00
• Low Price Target: $6.00
• Potential Upside/Downside: +223.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$244.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -103.02%
• Return on Assets: -39.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.38
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.60 per share
• Price / Book: 4.82

Miscellaneous

• Outstanding Shares: 299,360,000
• Free Float: 223,323,000
• Market Cap: $865.15 million
• Optionable: Optionable
• Beta: 2.18